98%
921
2 minutes
20
The renin-angiotensin system (RAS) is central to cardiovascular diseases such as hypertension and cardiomyopathy, yet the functions of many RAS genes remain unclear. This study developed a multi-label deep learning model to systematically annotate RAS gene functions and elucidate their roles in biological pathways. A total of 39,463 RAS-related publications from PubMed and PMC were processed into text format. Feature matrices were generated using TF-IDF and token processing, followed by dimensionality reduction via Principal Component Analysis (PCA). A Multi-Layer Perceptron (MLP) was applied for multi-label classification, with performance evaluated using Precision, F1-Score, Ranking Loss, and ROC-AUC metrics. The model outperformed traditional methods (SVM, Random Forest), achieving a Precision of 0.7474 and ROC-AUC of 0.8697. Grouping into three major biological branches improved interpretability and performance (Precision: 0.8312; ROC-AUC: 0.9182). In silico predictions were validated using extracellular vesicle (EV) proteomics and capillary Western assays in DOCA-salt hypertensive mice. Key genes-AGTR2, IRAP (LNPEP), Ywhas (SFN), EDNRA, and ESR2-were identified as critical RAS components. Notably, IRAP was markedly upregulated in hypertension and showed regulatory interactions with 14-3-3 proteins, modulating Nedd4-2, ACE2, and AGTR1 signaling. To our knowledge, this is the first integration of multi-label AI modeling with EV proteomics for RAS pathway annotation. This framework captures complex gene-pathway relationships, advancing systems-level understanding of RAS biology and revealing a novel IRAP/Ywha(s)/Nedd4-2-ACE2 interaction axis as a potential therapeutic target.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejphar.2025.178119 | DOI Listing |
Pediatr Nephrol
September 2025
Pediatric Nephrology Department, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain.
Copeptin, a stable glycopeptide derived from the precursor of arginine vasopressin (AVP), has emerged as a valuable surrogate biomarker for AVP due to its stability and ease of measurement. This narrative review explores the physiological role of copeptin, its utility as a diagnostic and prognostic biomarker in different kidney diseases, and its clinical relevance in renal tubular disorders. The clinical application of copeptin as a diagnostic biomarker is best established in the differential diagnosis of polyuria-polydipsia syndrome (PPS), distinguishing nephrogenic diabetes insipidus (NDI) from central diabetes insipidus (CDI) and primary polydipsia (PP).
View Article and Find Full Text PDFAnn Med
December 2025
Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China.
Purpose: End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and delay the progression of chronic kidney disease. We aim to perform a comprehensive analysis of current clinical evidence on the use of sacubitril/valsartan in ESRD patients.
View Article and Find Full Text PDFClin Exp Nephrol
September 2025
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Background: Sacubitril/valsartan is typically prescribed for patients with heart failure and hypertension. We previously reported that sacubitril/valsartan provides comparable blood pressure (BP) reduction and superior tolerability compared to thiazide diuretics. This post hoc study aimed to compare the effects of sacubitril/valsartan and thiazide diuretics in patients with chronic kidney disease (CKD).
View Article and Find Full Text PDFPalliat Med Rep
August 2025
Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society (NVS), Karolinska Institutet, Huddinge, Sweden.
Background: Treatment with antihypertensives in patients with advanced cancer is often continued until very late in the disease trajectory, despite a considerable risk of hypotension.
Objectives: The aim of this study was to investigate the time of deprescribing of antihypertensive agents in patients with cancer receiving palliative care during their last year of life. The monitoring of blood pressure (BP) during treatment was also studied.
J Prim Care Community Health
September 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.
View Article and Find Full Text PDF